-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IFx-Hu20 in Cutaneous Squamous Cell Carcinoma (cSCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IFx-Hu20 in Cutaneous Squamous Cell Carcinoma (cSCC) Drug Details: IFx-Hu20 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IFx-Hu20 in Nonmelanomatous Skin Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IFx-Hu20 in Nonmelanomatous Skin Cancer Drug Details: IFx-Hu20 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IFx-Hu20 in Merkel Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IFx-Hu20 in Merkel Cell Carcinoma Drug Details: IFx-Hu20 is under development for the treatment of...
-
Product Insights
Merkel Cell Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Merkel Cell Carcinoma - Drugs In Development, 2023’, provides an overview of the Merkel Cell Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Basal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Basal Cell Carcinoma (Basal Cell Epithelioma) - Drugs In Development, 2023’, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Nonmelanomatous Skin Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Nonmelanomatous Skin Cancer - Drugs In Development, 2023’, provides an overview of the Nonmelanomatous Skin Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nonmelanomatous Skin Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMP-019 in Allergies
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMP-019 in Allergies report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.AMP-019 in Allergies Drug Details:Epinephrine is under development for the treatment of allergic reactions,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JMKX-1899 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JMKX-1899 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.JMKX-1899 in Non-Small Cell Lung Cancer Drug Details:JMKX-1899 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IFx-Hu20 in Basal Cell Carcinoma (Basal Cell Epithelioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IFx-Hu20 in Basal Cell Carcinoma (Basal Cell Epithelioma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IFx-Hu20 in Basal Cell Carcinoma (Basal Cell Epithelioma) Drug...